Opdivo is expected to see 2020 sales declines, but key upcoming readouts could drive growth in 2021

Within the pipeline, Ozanimod, Liso-cel, and Ide-cel all are expected to receive approval and have shown promising data

This bodes well for the CVR, but note that the timelines are tight, especially for Liso-cel